BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35535040)

  • 1. PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer.
    Guo J; Du X; Li C
    Biomed Res Int; 2022; 2022():4434887. PubMed ID: 35535040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic Value of PCMT1 Expression in Gastric Cancer and Its Regulatory Effect on Spindle Assembly Checkpoints].
    Wang Y; Zhang M; Zhang Z; Li B; Huang J; Li J; Geng Z; Zhang X; Song X; Wang L; Zuo L; Hu J
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1167-1175. PubMed ID: 38162070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCMT1 is an unfavorable predictor and functions as an oncogene in bladder cancer.
    Dong L; Li Y; Xue D; Liu Y
    IUBMB Life; 2018 Apr; 70(4):291-299. PubMed ID: 29517839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro Anti-malignant Property of PCMT1 Silencing and Identification of the SNHG16/miR-195/PCMT1 Regulatory Axis in Breast Cancer Cells.
    Zhang Z; Li F; Li Y; Li Z; Jia G
    Clin Breast Cancer; 2023 Apr; 23(3):302-316. PubMed ID: 36639265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCMT1 is a potential target related to tumor progression and immune infiltration in liver cancer.
    Liu J; Liu B; Li Y; Mi Z; Tan H; Rong P
    Eur J Med Res; 2023 Aug; 28(1):289. PubMed ID: 37596654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of protein-L-isoaspartate O-methyltransferase-1 (PCMT1) in cervical cancer.
    Shan L; Wang X; Li Y; Li L; Wu S; Xi X; Yang Y
    Transl Cancer Res; 2022 Aug; 11(8):2582-2590. PubMed ID: 36093534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer.
    Shen Y; Xue J; Yu J; Jiang Y; Bu J; Zhu T; Gu X; Zhu X
    World J Surg Oncol; 2022 Dec; 20(1):398. PubMed ID: 36517818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCMT1 knockdown attenuates malignant properties by globally regulating transcriptome profiles in triple-negative breast cancer cells.
    Saiding A; Maimaitiyiming D; Chen M; Yan F; Chen D; Hu X; Shi P
    PeerJ; 2023; 11():e16006. PubMed ID: 37953789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of LCN1 as a Potential Biomarker for Breast Cancer by Bioinformatic Analysis.
    Yang Y; Li F; Luo X; Jia B; Zhao X; Liu B; Gao R; Yang L; Wei W; He J
    DNA Cell Biol; 2019 Oct; 38(10):1088-1099. PubMed ID: 31424267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative analysis of prognostic value and immune infiltration of spindle and kinetochore-associated family members in breast cancer.
    Ding J; He X; Wang J; Cao G; Chen S; Yuan L; Chen B; Xiong M
    Bioengineered; 2021 Dec; 12(2):10905-10923. PubMed ID: 34845974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis.
    Han X; Long W; Liu Y; Xu J
    Front Surg; 2022; 9():985034. PubMed ID: 36338652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis.
    Zhang J; Li Y; Liu H; Zhang J; Wang J; Xia J; Zhang Y; Yu X; Ma J; Huang M; Wang J; Wang L; Li Q; Cui R; Yang W; Xu Y; Feng W
    J Exp Clin Cancer Res; 2022 Jan; 41(1):24. PubMed ID: 35033172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer.
    Ye H; Zhang N
    Comput Math Methods Med; 2021; 2021():1498924. PubMed ID: 34868337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.
    Han B; Zhen F; Zheng XS; Hu J; Chen XS
    BMC Cancer; 2022 Mar; 22(1):297. PubMed ID: 35313846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
    Li F; Sun H; Li Y; Bai X; Dong X; Zhao N; Meng J; Sun B; Zhang D
    BMC Cancer; 2021 Dec; 21(1):1305. PubMed ID: 34876062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
    Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
    BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein-L-isoaspartate (D-aspartate) O-methyltransferase protects cardiomyocytes against hypoxia induced apoptosis through inhibiting proapoptotic kinase Mst1.
    Yan G; Qin Q; Yi B; Chuprun K; Sun H; Huang S; Sun J
    Int J Cardiol; 2013 Oct; 168(4):3291-9. PubMed ID: 23647599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.
    Hunt BG; Wicker CA; Bourn JR; Lower EE; Takiar V; Waltz SE
    Breast Cancer Res Treat; 2020 Jun; 181(3):529-540. PubMed ID: 32342233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.